Corporate Presentation

July 2021

1

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

2

Poxel's Mission and Vision

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology

acetyl CoA

METABOLIC

INFLAMMATION

DISORDERS

(cellular energy

TISSUE

homeostasis

DEGENERATION

imbalances)

& CELL DEATH

apoptosis,

necrosis

3

Poxel's Increasing Focus on Rare Metabolic Diseases

A New Strategic Direction Building upon Recent Achievements

  • Following the recent approval of TWYMEEG® (Imeglimin) in Japan and associated potential future revenues, Poxel to accelerate and expand rare metabolic disease programs
  • In rare metabolic diseases, first leveraging our internal platforms: dTZD and direct AMPK activators

o

o

Plan to advance 1 program in ALD into a pivotal study

Initiating PXL065 and PXL770 Phase 2a clinical Proof-of-Concept (POC) studies in adrenoleukodystrophy (ALD) in early 2022; Data expected Q4 2022

  1. Faster-to-marketstrategy with goal to launch an additional rare disease development program in 2022

•

o

o

Continued commitment to non-alcoholic steatohepatitis (NASH)

Plan to advance 1 program in NASH into a pivotal study

Patient screening is finished and enrolment in DESTINY Phase 2 trial with PXL065 is now expected to complete Q3 2021; Results anticipated Q3 2022

o

4

Future development of PXL770 in NASH to be evaluated pending PXL065 DESTINY Phase 2 data in NASH and Phase 2 POC results in ALD

TWYMEEG® (Imeglimin): Approved in Japan

Partnered in Asia1 with Diabetes Market Leader, Sumitomo Dainippon Pharma

  • June 23rd Approval in Japan triggered:
  1. 3rd and final tranche of EUR 13.5 million from IPF loan received June 30, 2021

o Milestone payment of ~EUR 13.2 million (USD 15.8 million)2 from Sumitomo in July

•

•

Target launch expected in 2021

Future potential development milestone payments and sales-based payments of up to approx. EUR 200 million (USD 230 million) 3, and double-digitescalating royalties

Business Opportunity Japan: Maximize Product Profile

  • Sumitomo #1 diabetes franchise; Guidance FY20 USD 900 million4
  • DPP4i's are prescribed to 80% T2D patients5
  • Limited treatment options for selected populations, including elderly and patients with renal impairment
    • elderly patients account for ~60% of T2D in Japan
  • TIMES program observed to show robust efficacy with favorable safety and tolerability profile
    • as Monotherapy and as an Add-on Therapy

1. Including: Japan, China, South Korea, Taiwan, Indonesia, Vietnam, Thailand,

2. Currency exchange rate at the date of the approval (23 June 2021)

Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos

3. Currency exchange rate at the date of the agreement (30 Oct 2017)

5

  1. Sumitomo fiscal year April-March.
  2. IQVIA data FY2016 and NDB data FY2016.

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Poxel SA published this content on 13 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 July 2021 08:34:05 UTC.